Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M P Saunders

Showing results (31-40 of 53) with videos related to

Pageof 6
Sort By:
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|February 19, 2026
Association of patient factors and health-related quality of life with weight changes during chemotherapy for colorectal cancer: secondary analysis of the SCOT trialT S Varghese, S Faithfull, A Frampton, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|October 11, 2007
A prospective observational study of chemotherapy-related nausea and vomiting in routine practice in a UK cancer centreA Molassiotis, M P Saunders, J Valle, et al.
ESMO Open|November 3, 2022
CXD101 and nivolumab in patients with metastatic microsatellite-stable colorectal cancer (CAROSELL): a multicentre, open-label, single-arm, phase II trialM P Saunders, J Graham, D Cunningham, et al.
Biochemical Pharmacology|February 29, 2000
The relative importance of NADPH: cytochrome c (P450) reductase for determining the sensitivity of human tumour cells to the indolequinone EO9 and related analogues lacking functionality at the C-2 and C-3 positionsM P Saunders, M Jaffar, A V Patterson, et al.
The Journal of Clinical Endocrinology and Metabolism|December 17, 1997
A novel cyclic adenosine monophosphate analog induces hypercalcemia via production of 1,25-dihydroxyvitamin D in patients with solid tumorsM P Saunders, A J Salisbury, K J O'Byrne, et al.
Cancer Chemotherapy and Pharmacology|August 3, 2010
Phase II study of short-course capecitabine plus oxaliplatin (XELOX) followed by maintenance capecitabine in advanced colorectal cancer: XelQuali studyT Waddell, S Gollins, W Soe, et al.
Anticancer Research|March 12, 1998
A phase II study evaluating the effect of tamoxifen on DNA repair in melanoma patients treated with dacarbazineM P Saunders, A J Salisbury, K J O'Byrne, et al.
British Journal of Cancer|July 24, 2008
Reciprocal relationship between expression of hypoxia inducible factor 1alpha (HIF-1alpha) and the pro-apoptotic protein bid in ex vivo colorectal cancerM M Seenath, D Roberts, C Cawthorne, et al.
Cancer Treatment and Research Communications|March 1, 2022
Clinico-pathological predictors of clinical complete response in rectal cancerP Mbanu, E Vasquez Osorio, H Mistry, et al.
British Journal of Cancer|August 7, 2008
A phase II study evaluating the use of concurrent mitomycin C and capecitabine in patients with advanced unresectable pseudomyxoma peritoneiA L Farquharson, N Pranesh, G Witham, et al.
Pageof 6

Showing results (31-40 of 53) with videos related to

Sort By:
Pageof 6
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|February 19, 2026
Association of patient factors and health-related quality of life with weight changes during chemotherapy for colorectal cancer: secondary analysis of the SCOT trialT S Varghese, S Faithfull, A Frampton, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|October 11, 2007
A prospective observational study of chemotherapy-related nausea and vomiting in routine practice in a UK cancer centreA Molassiotis, M P Saunders, J Valle, et al.
ESMO Open|November 3, 2022
CXD101 and nivolumab in patients with metastatic microsatellite-stable colorectal cancer (CAROSELL): a multicentre, open-label, single-arm, phase II trialM P Saunders, J Graham, D Cunningham, et al.
Biochemical Pharmacology|February 29, 2000
The relative importance of NADPH: cytochrome c (P450) reductase for determining the sensitivity of human tumour cells to the indolequinone EO9 and related analogues lacking functionality at the C-2 and C-3 positionsM P Saunders, M Jaffar, A V Patterson, et al.
The Journal of Clinical Endocrinology and Metabolism|December 17, 1997
A novel cyclic adenosine monophosphate analog induces hypercalcemia via production of 1,25-dihydroxyvitamin D in patients with solid tumorsM P Saunders, A J Salisbury, K J O'Byrne, et al.
Cancer Chemotherapy and Pharmacology|August 3, 2010
Phase II study of short-course capecitabine plus oxaliplatin (XELOX) followed by maintenance capecitabine in advanced colorectal cancer: XelQuali studyT Waddell, S Gollins, W Soe, et al.
Anticancer Research|March 12, 1998
A phase II study evaluating the effect of tamoxifen on DNA repair in melanoma patients treated with dacarbazineM P Saunders, A J Salisbury, K J O'Byrne, et al.
British Journal of Cancer|July 24, 2008
Reciprocal relationship between expression of hypoxia inducible factor 1alpha (HIF-1alpha) and the pro-apoptotic protein bid in ex vivo colorectal cancerM M Seenath, D Roberts, C Cawthorne, et al.
Cancer Treatment and Research Communications|March 1, 2022
Clinico-pathological predictors of clinical complete response in rectal cancerP Mbanu, E Vasquez Osorio, H Mistry, et al.
British Journal of Cancer|August 7, 2008
A phase II study evaluating the use of concurrent mitomycin C and capecitabine in patients with advanced unresectable pseudomyxoma peritoneiA L Farquharson, N Pranesh, G Witham, et al.
Pageof 6